All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
#EADV2024: Prevalence of psoriasis and pediatric psoriasis
By Ella Dixon
To update you on the exciting content presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress, we have collated our social media coverage. Catch up with our live social media posts relating to pediatric psoriasis and the prevalence, treatment options, and lifestyle factors associated with psoriasis below.
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
Mona ElKalioby, @monaelkalioby, @CairoUniv, presents a challenging case of pediatric plaque #psoriasis associated with LRBA deficiency. For systemic condition, the patient was treated with systemic corticosteroids (methylprednisolone),… pic.twitter.com/11LcxEg6zI
CONGRESS | #EADVCongress | PRESENTATION
Amy Paller, @paller_lab, @NUFeinbergMed, discusses recent treatment advances in pediatric #psoriasis.
▪️ Topicals: Roflumilast (PDE4 inhibitor) cream 0.3% and foam are approved for once-daily use in children aged 6-17 years, with a phase… pic.twitter.com/8jWEYf8Zaq— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
CONGRESS | #EADVCongress | PRESENTATION
Marieke Seyger, @radboudumc, shares insights on recategorization of disease severity in pediatric #psoriasis. They highlight that:
▪️ Current adult definitions are not applicable to pediatric patients. Applying the adult ‘rule of tens’,… pic.twitter.com/6SmsTEeiCI— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
CONGRESS | #EADVCongress | PRESENTATION@Satveer_Mahil, @KingsCollegeLon, shares insights on sustaining #psoriasis remission.
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
▪️ Early intervention with biologics can improve outcomes and allow for potential dose reductions, thereby reducing drug burden.
▪️ Two personalized and… pic.twitter.com/1we2xo35ob
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
Hok Bing Thio @HokThio, @ErasmusMC, discusses population differences in #psoriasis, highlighting that:
▪️ Psoriasis is more prevalent in adults than in children.
▪️ While the prevalence is lower, more severe forms of psoriasis are observed… pic.twitter.com/b7lOfAoNIp
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
Jo LW Lambert, @ugent @uzgent shares insights on therapeutic drug monitoring in patients with psoriasis.
They discuss the potential benefits and limitations of therapeutic drug monitoring, and provide an overview of two ongoing clinical… pic.twitter.com/dN11i0u209
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 26, 2024
Vanda Bondare-Ansberga, @RigaStradinsUni discusses the ethical aspects of psoriasis.
They highlight stigmatization, access, resource allocation, and the integration of new treatments. They also raise the need for patient involvement in… pic.twitter.com/EjCrq6hEoS
Your opinion matters
11 votes - 35 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox